Disseminated Intravascular Coagulation (DIC) Treatment Market - 2024-2031
Global Disseminated Intravascular Coagulation (DIC) Treatment Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2031 growing at a CAGR of YY% during the forecast period 2024-2031.
Disseminated intravascular coagulation (DIC) is a rare condition that causes abnormal blood clotting throughout the body's blood vessels. In disseminated intravascular coagulation, abnormal clumps of thickened blood (clots) form inside blood vessels. These abnormal clots use up the blood's clotting factors, which can lead to massive bleeding in other places.
Some of these clots can clog the vessels and cut off the normal blood supply to organs such as the liver, brain, or kidneys. Lack of blood flow can damage and cause major injury to the organs.
Market Dynamics
Increasing incidence of sepsis
The increasing prevalence of sepsis acts as a significant driver for market growth. Disseminated intravascular coagulation is a common complication of sepsis. In sepsis, the body's immune response triggers widespread activation of the coagulation system. This can lead to the formation of blood clots in small blood vessels throughout the body.
For instance, according to the World Health Organization Report 2023, there were 48.9 million cases and 11 million sepsis-related deaths worldwide which accounted for almost 20% of all global deaths. Also, almost half of all global sepsis cases occurred among children, with an estimated 20 million cases and 2.9 million global deaths in children under 5 years of age.
Additionally, according to the National Institute of Health Report 2022, nine observational studies involving 324,020 Chinese patients (9,587 patients with sepsis) were analyzed. Four hospital-wide studies involving 301,272 patients showed pooled prevalence and mortality of 3.8% and 26% respectively. Hence, the increasing incidence of sepsis can lead to the main cause of disseminated intravascular coagulation.
Furthermore, significant growth drivers such as the increasing awareness regarding DIC, rising geriatric population, and increasing bleeding disorders are expected to drive the market in the forecast period.
Side effects of treatment drugs
Heparin is also used to prevent blood clotting during open-heart surgery, bypass surgery, kidney dialysis, and blood transfusions. However, it has some side effects which include constipation, backaches, abnormal stomach pains, bleeding gums, heavy bleeding from wounds, severe headache, and blood in the urine. Thus, the above factors can hamper the market growth.
Segment Analysis
The global disseminated intravascular coagulation (DIC) treatment market is segmented based on type, treatment, route of administration, end user and region.
The anticoagulant medications segment accounted for approximately 42.8% of the market share
The anticoagulant medications segment is expected to hold the largest market share over the period forecast. Anticoagulant medications are a class of drugs that help prevent blood clots by interfering with the body's blood clotting mechanism. These medications such as heparin are commonly used to treat and prevent conditions associated with disseminated intravascular coagulation.
The use of heparin in DIC depends on the underlying cause of the condition. DIC can be triggered by various medical conditions such as sepsis, trauma, malignancy, or obstetric complications. In cases where sepsis is the underlying cause of DIC, anticoagulant therapy with heparin is considered.
For instance, according to clinicaltrials.gov, on November 18, 2023, China Medical University conducted a clinical trial to estimate the efficacy of unfractionated heparin(UFH) on ICU mortality in severe sepsis with suspected disseminated intravascular coagulation (DIC). It is currently in phase 3 and the expected study completion date is June 2025.
Geographical Analysis
North America is expected to hold a significant position in the global disseminated intravascular coagulation (DIC) treatment market share
The global disseminated intravascular coagulation (DIC) treatment market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.
North America has maintained a significant market proportion due to factors such as the rising prevalence of cancers, anticoagulant drug launches, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.
Disseminated Intravascular Coagulation (DIC) can be associated with cancer, and it is often seen as a complication of certain malignancies. Cancer-associated DIC is typically observed in advanced stages of cancer and is more common in specific types of cancers. For instance, In 2022, there is an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.
Additionally, drug launches from key players help in region growth. For instance, in June 2023, Techdow USA Inc. launched its 30mg, 40mg, 60mg, 80mg, 100mg, 120mg, and 150mg strengths of generic Enoxaparin Sodium (Preservative Free) Prefilled Syringes. Enoxaparin is made up of a complex blend of low molecular weight substances (oligosaccharides) derived from heparin. Hence, due to the above factors, it is expected to drive the region’s growth
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global disseminated intravascular coagulation (DIC) treatment market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, reagents, and drug launches, and consultations worldwide. With the outbreak of the pandemic, many treatment centers faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the disseminated intravascular coagulation (DIC) treatment market is expected to be moderately affected over the forecast period.
Market Segmentation
By Type
• Acute
• Chronic
By Treatment
• Anticoagulant medications
Heparin
Gabexate
• Plasma transfusions
By Route of Administration
• Oral
• Intravenous
By End User
• Hospital
• Specialty Clinics
• Ambulatory Care
• Others
By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Merck KGaA, Sanofi S.A, Enzo Life Sciences, Inc., KATSURA CHEMICAL CO. LTD, Biomol GmbH, Pfizer Inc., B. Braun Medical Inc., Intelicure Lifesciences, Baxter International Inc., Syntex S.A among others.
Why Purchase the Report?
• To visualize the global disseminated intravascular coagulation (DIC) treatment market segmentation based on type, treatment, route of administration, end users, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global disseminated intravascular coagulation (DIC) treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global disseminated intravascular coagulation (DIC) treatment market report would provide approximately 71 tables, 69 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Type
- 3.2. Snippet by Treatment
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by End Users
- 3.5. Snippet by Region
- 4. Market Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing incidence of sepsis
- 4.1.1.2. YY
- 4.1.2. Restraints
- 4.1.2.1. Side effects of treatment drugs
- 4.1.2.2. YY
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. DMI Opinion
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
- 7. By Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
- 7.2. Acute*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Chronic
- 8. By Treatment
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 8.1.2. Market Attractiveness Index, By Treatment
- 8.2. Anticoagulant medications*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.2.3. Heparin
- 8.2.4. Gabexate
- 8.3. Plasma transfusions
- 9. By Route of Administration
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.1.2. Market Attractiveness Index, By Route of Administration
- 9.2. Oral*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Intravenous
- 10. By End Users
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 10.1.2. Market Attractiveness Index, By End Users
- 10.2. Hospital*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Specialty Clinics
- 10.4. Ambulatory Care
- 10.5. Others
- 11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.7.1. U.S.
- 11.2.7.2. Canada
- 11.2.7.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.7.1. Germany
- 11.3.7.2. UK
- 11.3.7.3. France
- 11.3.7.4. Italy
- 11.3.7.5. Spain
- 11.3.7.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.4.7.1. Brazil
- 11.4.7.2. Argentina
- 11.4.7.3. Rest of South America
- 11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.7.1. China
- 11.5.7.2. India
- 11.5.7.3. Japan
- 11.5.7.4. Australia
- 11.5.7.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 12. Competitive Landscape
- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis
- 13. Company Profiles
- 13.1. Merck KGaA
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
- 13.2. Sanofi S.A
- 13.3. Enzo Life Sciences, Inc.,
- 13.4. KATSURA CHEMICAL CO. LTD
- 13.5. Biomol GmbH
- 13.6. Pfizer Inc.
- 13.7. B. Braun Medical Inc.
- 13.8. Intelicure Lifesciences
- 13.9. Baxter International Inc.
- 13.10. Syntex S.A
- LIST NOT EXHAUSTIVE
- 14. Appendix
- 14.1. About Us and Services
- 14.2. Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook